<DOC>
	<DOCNO>NCT01603615</DOCNO>
	<brief_summary>This study evaluate long-term safety BOTOX® ( botulinum toxin Type A ) treatment pediatric upper limb spasticity .</brief_summary>
	<brief_title>BOTOX® Open-Label Treatment Pediatric Upper Limb Spasticity</brief_title>
	<detailed_description />
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>Minimum weight 10 kg/22 lb Upper limb spasticity due cerebral palsy stroke Muscular dystrophy , myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis , mitochondrial disease Uncontrolled epilepsy Botulinum Toxin therapy serotype condition within last 3 month History surgical intervention upper limb within 1 year , plan surgery limb study</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>